Want to join the conversation?
$ILMN said oncology shipments grew 9% adjusted for the large HiSeq X shipments seen in 1Q15. This growth rate is lower than what is typically seen from this market due to a large number of orders shipped in the prior year period. The company expects expanded adoption in 2016, fueled in part by the TruSight Tumor 170 launch later this year.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?